GSK seeks marketing approval for lapatinib ditosylate

Published: 2006-11-17 06:57:00

Updated: 2006-11-17 06:57:00

Last month, GlaxoSmithKline plc (GSK) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for approval to market Tykerb (lapatinib ditosylate) in combination with Xeloda (capecitabine), for the treatment of advanced or metastatic ErbB2 (HER2) ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK